Theravance Biopharma
TBPH
TBPH
118 hedge funds and large institutions have $449M invested in Theravance Biopharma in 2021 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 42 increasing their positions, 21 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
1.85% less ownership
Funds ownership: 84.41% → 82.56% (-1.9%)
49% less capital invested
Capital invested by funds: $882M → $449M (-$433M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Holders
118
Holding in Top 10
1
Calls
$8.44M
Puts
$4.48M
Top Buyers
| 1 | +$36.5M | |
| 2 | +$27.7M | |
| 3 | +$25.2M | |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$18.5M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$11.9M |
Top Sellers
| 1 | -$62.7M | |
| 2 | -$60.1M | |
| 3 | -$20.1M | |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$10.6M |
| 5 |
HCM
Highbridge Capital Management
New York
|
-$8.53M |